Döhner H, Wei A H, Appelbaum F R, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN[J]. Blood, 2022,140(12): 1345-1377.
[2]
Daver N G, Iqbal S, Renard C, et al. Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis[J]. J Hematol Oncol, 2023,16(1):19-32.
[3]
Hunter A M,Sallman D A.Current status and new treatment approaches in TP53 mutated AML[J].Best Pract Res Clin Haematol,2019,32(2):134-144.
Loschi M, Fenaux P, Cluzeau T. How I treat TP53-mutated acute myeloid leukemia and myelodysplastic syndromes [J]. Cancers (Basel), 2022,14(18): 4519-4530.
Dinardo C D, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia[J]. Blood, 2019, 133(1):7-17.
[9]
Becker H, Pfeifer D, Ihorst G, et al. Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia[J]. Ann Hematol, 2020, 99(7): 1551-1560.
[10]
Chen S S, Sun Q, Cao L, et al.Efficacy and safety of decitabine combined with low-dose cytarabine, aclarubicin, and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation [J].Chin Med J(Engl), 2020, 134(12):1477-1479.
[11]
Daver N G,Vyas P, Kambhampati S, et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results [J]. J Clin Oncol,2022:40(16):7020-7023.
[12]
Sallman D A, Komrokji R S, DeZern A E, et al. Long term follow-up and combined phase 2 results of eprenetapopt(APR-246) and azacitidine(AZA) in patients with TP53 mutant myelodysplastic syndromes(MDS) and oligoblastic acute myeloid leukemia(AML) [J]. Blood, 2021,138(suppl 1): 246-248.
[13]
Guillermo G M, Aaron D G, Eric S W, et al. Phase Ⅰ and expansion study of eprenetapopt (APR-246) in combination with venetoclax(VEN) and azacitidine(AZA) in TP53-mutant acute myeloid leukemia(AML) [J]. Blood, 2021,138(suppl 1): 3409-3413.
[14]
Brunner A M,Esteve J,Porkka K,et al. Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS): updated results from a phase 1b study[J].Blood, 2020,136 (Suppl 1):1-2.
[15]
Chen S, Wu J L, Liang Y, et al. Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site[J]. Cancer Cell, 2021, 39(2): 225-239.
[16]
Short N J, Montalban-Bravo G, Hwang H, et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia[J]. Blood Adv, 2020, 4(22):5681-5689.
[17]
Xu J,Wang J,Hu Y,et al.Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity[J].Cell Death Dis,2014,5(3): e1108-e1116.
[18]
Bernard E, Nannya Y, Hasserjian R P, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes[J]. Nat Med, 2020,26(10): 1549-1556.
2023, Vol. 34 
